The Indian pharma industry has grown at a compounded growth rate of ~11% in the domestic market and ~16% in exports over the last two decades
The price increases are due to the rising costs of raw materials.
Tiger can no longer make an important biotin intermediate using a DSM patented process.
Building upon the momentum gained by pharma sector during the pandemic, Indian Pharmaceutical Alliance is leaving no stone unturned to create a faster road to recovery.
The Govt. launched the PLI scheme for bulk drugs with a financial outlay of Rs 6,940 crores across 53 APIs over 6 years.
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
ranules now has a total of 38 ANDA approvals from US FDA.
India business grew 11.8% YoY vs mid-single digit industry growth.
The company continued to maintain clear FDA status across its plants and has received 12 ANDA approvals during 9MFY21
The centralized marketing authorization granted by the EC is valid in all EU Member
Subscribe To Our Newsletter & Stay Updated
